

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 A61K38/06 A61K38/07 A61K39/395 C12N15/11 A61K48/00  
A61P35/02

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, BIOSIS, EMBASE, Sequence Search, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/10383 A (VERTEX PHARMACEUTICALS INCORPORATED; GOLEC, JULIAN; CHARIFSON, PAUL; B) 15 February 2001 (2001-02-15)	1,2, 10-12, 24,25, 45-48
Y	see claims 1-10, table 1 and pages 50-52	1-61
X	WO 01/94351 A (VERTEX PHARMACEUTICALS INCORPORATED; CHARRIER, JEAN-DAMIEN; BRENCHLEY,) 13 December 2001 (2001-12-13)	1,2, 10-12, 24,25, 45-48
Y	see claims 1,7,9 and page 50 table 6	1-61
X	US 2003/083296 A1 (ZHANG HONG ET AL) 1 May 2003 (2003-05-01)	1,2, 10-12, 24,25, 45-48
Y	see claims 1 and 14-18	1-61
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

**\* Special categories of cited documents:**

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

4 March 2005

Date of mailing of the international search report

17/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Merckling-Ruiz, V

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/25832 A (THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY) 27 May 1999 (1999-05-27)	1,2, 10-12, 24,25, 45-48
Y	see abstract, pages 29 and 37-38	1-61
X	WO 03/020767 A (YEDA RESEARCH AND DEVELOPMENT CO. LTD; WALLACH, DAVID; GONCHAROV, TANY) 13 March 2003 (2003-03-13) see abstract and claims	42-44
Y	VARFOLOMEEV E.E. ET AL.: "Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 is lethal prenatally." IMMUNITY, vol. 9, August 1998 (1998-08), pages 267-276, XP002320053 cited in the application see abstract	1-61
Y	SALMENA L. ET AL.: "Essential role for caspase-8 in T cell homeostasis and T cell mediated immunity." GENES AND DEVELOPMENT, vol. 17, 21 March 2003 (2003-03-21), pages 883-895, XP002320054 see abstract and page 892 left column	1-61
Y	KENNEDY N.J. ET AL.: "Caspase activation is required for T cell proliferation." J. EXP. MED., vol. 190, no. 12, 20 December 1999 (1999-12-20), pages 1891-1895, XP002320055 see abstract and pages 1894-1895	1-61
A	CHLICHIA K. ET AL.: "Caspase activation is required for nitric oxide-mediated CD95 (Apo1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells." BLOOD, vol. 91, no. 11, 1 June 1998 (1998-06-01), pages 4311-4320, XP002320056 see abstract	1-61
A	WANG J. AND LENARDO M.J.: "Roles of caspases in apoptosis, development and cytokine maturation revealed by homozygous gene deficiencies." J. CELL SCIENCE, vol. 113, 2000, pages 753-757, XP002320057 see the whole document	1-61

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0110383	A	15-02-2001	AT 266623 T	15-05-2004
			AU 6894800 A	05-03-2001
			DE 60010675 D1	17-06-2004
			DK 1163208 T3	16-08-2004
			EP 1163208 A2	19-12-2001
			ES 2219381 T3	01-12-2004
			JP 2003506389 T	18-02-2003
			PT 1163208 T	31-08-2004
			SI 1163208 T1	31-10-2004
			WO 0110383 A2	15-02-2001
			US 2002132833 A1	19-09-2002
WO 0194351	A	13-12-2001	AU 7527901 A	17-12-2001
			CA 2409015 A1	13-12-2001
			EP 1289993 A1	12-03-2003
			JP 2003535865 T	02-12-2003
			WO 0194351 A1	13-12-2001
			US 2002045623 A1	18-04-2002
US 2003083296	A1	01-05-2003	US 6258600 B1	10-07-2001
			AU 2784801 A	31-07-2001
			EP 1248858 A1	16-10-2002
			JP 2003520052 T	02-07-2003
			WO 0153541 A1	26-07-2001
WO 9925832	A	27-05-1999	US 2002177565 A1	28-11-2002
			AU 757553 B2	27-02-2003
			AU 1699399 A	07-06-1999
			CA 2309343 A1	27-05-1999
			EP 1032670 A1	06-09-2000
			JP 2001523457 T	27-11-2001
			WO 9925832 A1	27-05-1999
WO 03020767	A	13-03-2003	BR 0212289 A	14-09-2004
			CA 2458985 A1	13-03-2003
			EP 1423429 A2	02-06-2004
			WO 03020767 A2	13-03-2003
			JP 2005501905 T	20-01-2005
			MX PA04002104 A	07-06-2004